Posted by Michael Wonder on 03 Jun 2024
Johnson & Johnson submits application to the EMA seeking approval of subcutaneous formulation of Rybrevant (amivantamab) for the treatment of patients with EGFR mutated non-small cell lung cancer
31 May 2024 - Submission is supported by data from the Phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology Annual Meeting.
Janssen-Cilag announced today the submission of an application for the extension of the Rybrevant (amivantamab) marketing authorisation (line extension) to the EMA.
